🇺🇸 ritonavir-boosted fosamprenavir in United States
14 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 14
Most-reported reactions
- Virologic Failure — 5 reports (35.71%)
- Creatinine Renal Clearance Decreased — 1 report (7.14%)
- Diabetes Insipidus — 1 report (7.14%)
- Fanconi Syndrome — 1 report (7.14%)
- Hepatitis Acute — 1 report (7.14%)
- Iridocyclitis — 1 report (7.14%)
- Kaposi'S Sarcoma — 1 report (7.14%)
- Laryngeal Pain — 1 report (7.14%)
- Mycobacterium Avium Complex Infection — 1 report (7.14%)
- Pancreatitis Acute — 1 report (7.14%)
Other Infectious Disease approved in United States
Frequently asked questions
Is ritonavir-boosted fosamprenavir approved in United States?
ritonavir-boosted fosamprenavir does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for ritonavir-boosted fosamprenavir in United States?
The University of Texas Health Science Center, Houston is the originator. The local marketing authorisation holder may differ — check the official source linked above.